biliary tract cancer
Conditions
Interventions
case series:Tirelizumab + Nab-Paclitaxel + Gemcitabine
Sponsors
Shanghai Xuhui Central Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Pathological diagnosised as biliary tract cancer, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder carcinoma; 2. Potentially resectable, no distant metastasis, local progression; 3. At least one measurable lesion (RECIST 1.1); 4. ECOG performance status = 3 months; 7. Evaluated by the investigator as suitable for participating in the trial; 8. Potentially fertile male and female patients must consent to use an effective method of contraception throughout the study; 9. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. History of receiving systemic anti-tumor therapy; 2. History of allergic reactions to similar drugs; 3. Pregnant or lactating patients; 4. Pericardial effusion, uncontrolled pleural effusion, or clinically severe ascites(including ascites detected in physical examination or ascites required aspiration at the time of screening); 5. History of interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic diseases, including diabetes mellitus, hypertension, pulmonary fibrosis, and acute lung disease, et al.; 6. Severe cardiovascular disease, such as symptomatic coronary heart disease, grade II or higher congestive heart failure, uncontrolled arrhythmias, and myocardial infarction, occurred within 12 months before enrollment; 7. Other uncured malignancies; 8. Uncontrollable mental illness; 9. Any other factors that investigators considered inappropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| R0 Radical resection rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Event-free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactLiu Houbao
Shanghai Xuhui Central Hospital
Outcome results
None listed